Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study
Open Access
- 20 March 2012
- journal article
- research article
- Published by Hindawi Limited in Sarcoma
- Vol. 2012, 1-11
- https://doi.org/10.1155/2012/740279
Abstract
The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.Keywords
This publication has 15 references indexed in Scilit:
- Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of informationAnnals of Oncology, 2011
- Trabectedin for the treatment of advanced metastatic soft tissue sarcomaHealth Technology Assessment, 2010
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2010
- Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature reviewAnnals Of Oncology, 2009
- State-of-the-art approach in selective curable tumors: bone sarcomaAnnals of Oncology, 2008
- US Valuation of the EQ-5D Health StatesMedical Care, 2005
- Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)Sarcoma, 2005
- Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomasCancer, 2001
- Health-related Quality of Life Measured by the EORTC QLQ-C30: Reference Values From a Large Sample of the Swedish PopulationActa Oncologica, 2000
- Modeling Valuations for EuroQol Health StatesMedical Care, 1997